In recent years, the field of cancer immunotherapy has seen considerable progress due to the discovery of new therapies targeting immune checkpoint molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD1) and programmed cell death ligand 1 (PD-L1) [9]. This evidence concerns the gene CTLA4 and cancer.